Get alerts for new trials in your area by subscribing now
Active & Responsive
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
for
Germ Cell Tumor
Location: Indianapolis IN
Sponsor: Indiana University
Sex: All
Age: 18+
Code: NCT06937866
Phase 1, Phase 2, Recruiting
Active & Responsive
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
for
Head and Neck Cancer
Location: Philadelphia PA
Sponsor: IBA Proton Therapy, Inc.
Sex: All
Age: 18+
Code: NCT07644585
Recruiting
Active & Responsive
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
for
Pediatric Tumor of CNS, Pediatric Tumor of Brain,
Location: Orange CA
Sponsor: Neonc Technologies, Inc.
Sex: All
Age: 5 - 18
Code: NCT06357377
Phase 1, Recruiting
Active & Responsive
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
for
Metastatic Urothelial Carcinoma,
Location: Spokane WA, Los Angeles CA
Sponsor: Summit Therapeutics
Sex: All
Age: 18+
Code: NCT07815665
Phase 2, Phase 3, Recruiting
Active & Responsive
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
for
HSIL, High Grade Squamous Intraepithelial Lesion,
Location: San Francisco CA
Sponsor: University of California, San Francisco
Sex: All
Age: 21+
Code: NCT06949800
Phase 2, Recruiting
Active & Responsive
Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib
for
HER2+ Metastatic Breast Cancer (MBC)
Location: Durham NC
Sponsor: Duke University
Sex: Female
Age: 18+
Code: NCT06983691
Recruiting
Active & Responsive
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation,
Location: Boston MA, Chicago IL, Minneapolis MN, Los Angeles CA
Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)
Sex: All
Age: 12 - 17
Code: NCT07286292
Phase 2, Recruiting
Active & Responsive
Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients
for
Colorectal Cancer
Location: Palo Alto CA
Sponsor: Stanford University
Sex: All
Age: 18+
Code: NCT07403981
Recruiting
Active & Responsive
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
for
Acute Myeloid Leukemia, Pediatric AML
Location: Houston TX
Sponsor: Baylor College of Medicine
Sex: All
Age: 0 - 30
Code: NCT07059975
Early Phase 1, Recruiting
Active & Responsive
Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors
for
Periampullary Neoplasms, Pancreatic Cancer,
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sex: All
Age: 18+
Code: NCT07360119
Recruiting
Active & Responsive
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
for
Prostate Cancer Screening
Location: Durham NC, Hardeeville SC
Sponsor: Uro-1 Medical
Sex: Male
Age: 18+
Code: NCT06830265
Recruiting
Active & Responsive
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
for
Uveal Melanoma
Location: Philadelphia PA, Toronto, Nashville TN, Scottsdale AZ
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT07804186
Phase 3, Recruiting
Active & Responsive
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
for
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma,
Location: Washington D.C. DC
Sponsor: Children's National Research Institute
Sex: All
Age: 3 - 25
Code: NCT07664176
Phase 1, Recruiting
Active & Responsive
Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
for
Esophageal Carcinoma, Gastric Cancer (Diagnosis),
Location: Orange CA
Sponsor: University of California, Irvine
Sex: All
Age: 18+
Code: NCT07795749
Phase 2, Recruiting
Active & Responsive
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma